Contineum initiates dosing in phase 1b Chronic Pain trial of PIPE-791

Contineum (CTNM) Therapeutics “initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor. PIPE-791 is being evaluated for the treatment of chronic pain associated with two separate indications, osteoarthritis and low back pain. The Company expects to enroll approximately 40 patients at up to five sites in the U.S., and a treatment duration of 28 days. Contineum anticipates topline data from the PIPE-791 Phase 1b chronic pain trial in early 2026.”